GSK plc (LSE:GSK) is one of the cornerstones of the FTSE 100 and a household name in global healthcare. The biopharma group, which employs around 66,840 people worldwide, develops vaccines, specialty medicines and general medicines across respiratory, immunology, oncology, HIV and infectious disease. Since spinning off its consumer-health arm as Haleon in 2022, GSK has reinvented itself as a more focused, R&Amp;D-driven pharmaceutical company — and the market is increasingly judging GSK shares on the strength of that pipeline and the dependability of its Dividend.

On 5 June 2026, GSK shares traded at 1,918.50p, up 0.87% on the day, with about 585,170 shares changing hands. The group's Market Capitalisation stood at roughly £77.04bn, on a price-to-Earnings (P/E) ratio of 13.15 and Earnings Per Share (EPS) of 1.42 GBP. With a Yield in the region of 3.5%, GSK remains a core consideration for income investors scanning UK dividend stocks for defensive, Blue-Chip exposure. This article unpacks the dividend, its sustainability and the risks ahead.

What the Company Does

GSK is a research-led biopharmaceutical company structured around two main commercial engines: Vaccines and Specialty Medicines, which drive growth, and General Medicines, which provides scale and cash. Its Vaccine Franchise spans shingles (Shingrix), meningitis, RSV (Arexvy) and other infectious diseases, while Specialty Medicines includes HIV treatments through ViiV Healthcare, respiratory Biologics, oncology and immunology.

The group's value rests on its scientific pipeline, its Manufacturing scale, and the recurring nature of healthcare Demand, which is relatively insulated from economic cycles. Since the Haleon demerger, management has set out ambitious medium-term targets for sales and profit growth, anchored by new product launches and pipeline progression. For investors in GSK shares, the central question is whether that growth can offset the inevitable Patent expiries that all large pharma companies face — and whether it can fund a steadily rising dividend.

Latest Share Price and Market Snapshot

As of 5 June 2026, the headline numbers for GSK shares were:

  • Share price: 1,918.50p
    • Daily move: +0.87%
    • Volume: 585,170 shares
    • Market capitalisation: £77.04bn
    • P/E ratio: 13.15
    • EPS: 1.42 GBP
    • Employees: approximately 66,840

A P/E of 13.15 is modest for a large-cap pharmaceutical, reflecting the market's historic caution around GSK's pipeline depth and litigation overhangs relative to higher-rated global peers. With EPS of 1.42 GBP comfortably exceeding the annual dividend, the earnings backdrop provides solid support for the payout — a key reassurance for income investors weighing GSK shares.

Dividend Overview

The GSK dividend was deliberately rebased following the 2022 Haleon demerger. With the cash-generative consumer-health Business carved out, GSK reset its payout to a more sustainable level — a reduction of around 31% on the previous forecast — and adopted a new progressive policy targeting a payout of roughly 40%–60% of earnings, averaged across Investment cycles. A share consolidation accompanied the split, adjusting the per-share figures while keeping the aggregate sterling spend broadly intact.

This reset was a strategic choice rather than a sign of distress: it freed up Capital to reinvest in R&D and strengthen the Balance Sheet while still offering shareholders a meaningful, growing income. GSK pays its dividend quarterly, which appeals to income investors who value regular Cash Flow.

Latest Dividend Payment and Yield

For the 2025 financial year, GSK declared a total ordinary dividend of 66p per share, including an 18p fourth-quarter payment. For 2026, the group has guided to a higher full-year dividend of 70p per share, consistent with its progressive policy. The quarterly schedule sees payments spread through the year, with the Q1 2026 dividend payable in July 2026 and subsequent instalments through the year and into early 2027.

Measured against the 5 June 2026 share price of 1,918.50p, the 2025 dividend of 66p implies a trailing yield of approximately 3.4%, while the guided 70p for 2026 points to a forward yield of around 3.6%. That places GSK comfortably above the FTSE 100 average and squarely within the income camp.

Dividend History: Growth, Cuts or Stability

GSK's dividend history pivots on 2022. For years before the demerger, the legacy GlaxoSmithKline dividend was held flat at 80p per share — generous but stagnant, and increasingly questioned as cover thinned. The Haleon split allowed management to draw a line under that era, resetting the payout to a lower, better-covered base from which it could grow again.

Since the reset, the trajectory has been one of modest, deliberate growth: a clear progression from the rebased level towards the 66p paid for 2025 and the 70p guided for 2026. The story is therefore one of a single, strategic cut followed by re-established progression — a healthier setup for long-term Shareholder returns than the previously frozen, thinly covered payout.

Can the Dividend Be Sustained?

The GSK dividend looks well supported. With EPS of 1.42 GBP against a 2025 dividend of 66p, the earnings Payout Ratio is comfortably below 50% — squarely within management's stated 40%–60% range and leaving substantial headroom. Strong cash generation from the vaccines and specialty franchises further underpins the distribution.

The principal threats to sustainability are operational rather than financial: patent expiries on key products, pipeline setbacks, and litigation provisions can all dent earnings. However, the low payout ratio means GSK could absorb a degree of earnings pressure without endangering the dividend. On balance, the combination of conservative cover, recurring healthcare demand and a clearly articulated policy makes the dividend one of the more secure among large UK dividend stocks — provided the pipeline delivers.

Earnings, Valuation and Balance Sheet Signals

GSK's earnings have been driven by strong vaccine sales — particularly Shingrix and the RSV launch — alongside growth in HIV and specialty medicines. The P/E of 13.15 suggests the market is not paying a premium for that growth, partly reflecting concerns about future patent cliffs, including the HIV portfolio, and the periodic drag of legal provisions.

The balance sheet has strengthened since the demerger, with management prioritising deleveraging alongside R&D investment. The bull case for GSK shares is a re-rating if the pipeline converts into approved, commercialised products that reassure the market about post-patent-cliff growth. The bear case is that earnings plateau as older products fade faster than new ones ramp. The valuation, dividend cover and pipeline newsflow are therefore the signals to track.

Why the Stock Matters to Income Investors

For income investors, GSK ticks several boxes: a defensive, non-cyclical business; a yield around 3.4% comfortably above the index; quarterly payments; and a low, well-covered payout ratio that supports the prospect of continued dividend growth. As one of the largest blue-chip stocks on the London market, it also offers Liquidity and the Diversification benefits of healthcare exposure.

The trade-off is that GSK is no longer the ultra-high-yield, flat-dividend stock it was before 2022. Income investors seeking maximum current yield may prefer other names, but those prioritising dividend quality, cover and sustainable growth will find GSK's rebased policy attractive. It is, in short, a quality income holding rather than a yield-maximising one within UK equities.

Key Risks for Investors

Patent expiry is the defining long-term risk for any large pharma group, and GSK faces the eventual loss of exclusivity on important products, including parts of its HIV franchise. Pipeline risk is ever-present: clinical-trial failures or regulatory rejections can erase anticipated Revenue. Litigation — historically a periodic overhang for GSK — can result in sizeable provisions and headline Volatility.

Pricing pressure from governments and payers, particularly in the United States, threatens margins across the industry. Currency movements affect reported results given GSK's global footprint. Competition in vaccines and specialty medicines is intensifying. Any of these factors could weigh on earnings and, in an extreme scenario, on the capacity for dividend growth — though the low payout ratio provides a meaningful buffer.

What Could Move the Stock Next

Quarterly results and pipeline milestones are the key near-term catalysts, with the market watching vaccine sales momentum, RSV uptake, and progress in oncology and respiratory biologics. Regulatory decisions on key candidates, business-development activity and any updates to medium-term guidance could all move GSK shares.

Litigation developments remain a swing Factor for sentiment, as do US drug-pricing policy and the broader regulatory environment. On the income side, confirmation of the 70p 2026 dividend and any signals about the pace of future growth will matter to shareholders. As with all FTSE shares, macro sentiment towards defensive UK equities will also play a role.

Final Takeaway

GSK shares offer income investors a defensive, blue-chip healthcare holding with a rebased but progressively growing dividend. At 1,918.50p the yield of around 3.4% sits above the FTSE 100 average, and a payout ratio well within management's 40%–60% target leaves ample room for the guided rise to 70p in 2026 and beyond. The dividend looks one of the better-covered among large UK dividend stocks, with the main risks lying in patent expiries, pipeline execution and litigation rather than affordability. For income investors, GSK represents quality and sustainability over headline yield — though, as ever with UK equities, suitability depends on individual circumstances.